Cumberland Pharmaceuticals, which focuses on the acquisition of branded prescription products in hospital acute care and gastroenterology, filed terms Monday for its upcoming IPO. The company plans to offer 6.3 million shares at a price range of $14 to $16. The company filed to be traded on the NASDAQ with the ticker "CPIX." UBS is the lead manager on the deal.
